PubMed:32735992 / 1389-1535 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T42","span":{"begin":25,"end":29},"obj":"G_3"},{"id":"T43","span":{"begin":25,"end":29},"obj":"PG_10"},{"id":"T44","span":{"begin":25,"end":29},"obj":"PR:000003622"},{"id":"T45","span":{"begin":109,"end":127},"obj":"PG_18"},{"id":"T46","span":{"begin":109,"end":127},"obj":"PG_1"},{"id":"T47","span":{"begin":115,"end":127},"obj":"CHEBI:17089"},{"id":"T48","span":{"begin":115,"end":127},"obj":"BV_11"},{"id":"T49","span":{"begin":115,"end":127},"obj":"CHEBI:17089"},{"id":"T50","span":{"begin":135,"end":145},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":115,"end":127},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62925"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":135,"end":143},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":54,"end":62},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":115,"end":127},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"35","span":{"begin":135,"end":145},"obj":"Species"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Gene:59272"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":146},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"Covid19_manual_annotation_v2","denotations":[{"id":"T14","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"T29","span":{"begin":92,"end":103},"obj":"Phenomena"},{"id":"T3","span":{"begin":135,"end":145},"obj":"Species"},{"id":"T50","span":{"begin":109,"end":127},"obj":"Gene"},{"id":"T64","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T65","span":{"begin":44,"end":62},"obj":"Phenomena"},{"id":"T67","span":{"begin":41,"end":43},"obj":"Without"},{"id":"T70","span":{"begin":83,"end":91},"obj":"PositiveRegulation"},{"id":"T71","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T72","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"T77","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T78","span":{"begin":25,"end":29},"obj":"Gene"}],"relations":[{"id":"R37","pred":"of_a","subj":"T64","obj":"T14"},{"id":"R39","pred":"is_a","subj":"T67","obj":"T65"},{"id":"R65","pred":"has_a","subj":"T14","obj":"T65"},{"id":"R66","pred":"has_role","subj":"T64","obj":"T67"},{"id":"R67","pred":"of_a","subj":"T77","obj":"T78"},{"id":"R68","pred":"to","subj":"T29","obj":"T78"},{"id":"R69","pred":"is_a","subj":"T77","obj":"T70"},{"id":"R40","pred":"of_a","subj":"T3","obj":"T50"},{"id":"R42","pred":"is_a","subj":"T70","obj":"T29"},{"id":"R43","pred":"is_a","subj":"T50","obj":"T29"},{"id":"R44","pred":"of_a","subj":"T71","obj":"T72"}],"attributes":[{"id":"A49","pred":"Memo","subj":"T65","obj":"MESH:D004789"},{"id":"A14","pred":"tao:has_database_id","subj":"T14","obj":"Gene:59272"},{"id":"A30","pred":"tao:has_database_id","subj":"T72","obj":"Gene:59272"},{"id":"A52","pred":"tao:has_database_id","subj":"T78","obj":"Gene:59272"},{"id":"A34","pred":"Memo","subj":"T64","obj":"MESH:D011994"},{"id":"A51","pred":"Memo","subj":"T77","obj":"MESH:D011994"},{"id":"A3","pred":"tao:has_database_id","subj":"T3","obj":"Tax:2697049"},{"id":"A58","pred":"Memo","subj":"T29","obj":"MESH:D053585"},{"id":"A28","pred":"tao:has_database_id","subj":"T50","obj":"Gene:43740568"},{"id":"A35","pred":"Memo","subj":"T71","obj":"MESH:D011994"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"BioProject","uri":"https://www.ncbi.nlm.nih.gov/bioproject/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"},{"prefix":"HP","uri":"https://hpo.jax.org/app/browse/term/HP:"},{"prefix":"BioSample","uri":"https://www.ncbi.nlm.nih.gov/biosample/"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}

{"project":"Zoonoses","denotations":[{"id":"T14","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"T29","span":{"begin":92,"end":103},"obj":"Phenomena"},{"id":"T3","span":{"begin":135,"end":145},"obj":"Species"},{"id":"T50","span":{"begin":109,"end":127},"obj":"Gene"},{"id":"T64","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T65","span":{"begin":44,"end":62},"obj":"Phenomena"},{"id":"T67","span":{"begin":41,"end":43},"obj":"Without"},{"id":"T70","span":{"begin":83,"end":91},"obj":"PositiveRegulation"},{"id":"T71","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T72","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"T77","span":{"begin":4,"end":12},"obj":"Type"},{"id":"T78","span":{"begin":25,"end":29},"obj":"Gene"}],"relations":[{"id":"R37","pred":"of_a","subj":"T64","obj":"T14"},{"id":"R39","pred":"is_a","subj":"T67","obj":"T65"},{"id":"R40","pred":"of_a","subj":"T3","obj":"T50"},{"id":"R42","pred":"is_a","subj":"T70","obj":"T29"},{"id":"R43","pred":"is_a","subj":"T50","obj":"T29"},{"id":"R44","pred":"of_a","subj":"T71","obj":"T72"},{"id":"R65","pred":"has_a","subj":"T14","obj":"T65"},{"id":"R66","pred":"has_role","subj":"T64","obj":"T67"},{"id":"R67","pred":"of_a","subj":"T77","obj":"T78"},{"id":"R68","pred":"to","subj":"T29","obj":"T78"},{"id":"R69","pred":"is_a","subj":"T77","obj":"T70"}],"attributes":[{"id":"A49","pred":"Memo","subj":"T65","obj":"MESH:D004789"},{"id":"A52","pred":"tao:has_database_id","subj":"T78","obj":"Gene:59272"},{"id":"A34","pred":"Memo","subj":"T64","obj":"MESH:D011994"},{"id":"A30","pred":"tao:has_database_id","subj":"T72","obj":"Gene:59272"},{"id":"A58","pred":"Memo","subj":"T29","obj":"MESH:D053585"},{"id":"A35","pred":"Memo","subj":"T71","obj":"MESH:D011994"},{"id":"A3","pred":"tao:has_database_id","subj":"T3","obj":"Tax:2697049"},{"id":"A51","pred":"Memo","subj":"T77","obj":"MESH:D011994"},{"id":"A28","pred":"tao:has_database_id","subj":"T50","obj":"Gene:43740568"},{"id":"A14","pred":"tao:has_database_id","subj":"T14","obj":"Gene:59272"}],"text":"The designed therapeutic ACE2 would have no enzymatic activity while it could bear stronger interaction with Spike glycoprotein of the SARS-CoV-2."}